SEC Company Response from ADIAL PHARMACEUTICALS, INC. (ADIL) (CIK 0001513525) (AZR) — Oct 25, 2017
ADIAL PHARMACEUTICALS, INC. (ADIL) (CIK 0001513525)
Date: Oct. 25, 2017 · CIK: 0001513525 · Accession: 0001213900-17-010932
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-220368
Referenced dates: October 5, 2017
Letter
VIA EDGAR United States Securities Division of Corporation Finance Attention: Ms. Suzanne Hayes Re: Adial Pharmaceuticals, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed September 25, 2017 File No: 333-220368
Dear Ms. Hayes:
On behalf of our client, Adial Pharmaceuticals, Inc. (the “Company”), we submit this letter in response to comment 1 received from the staff (the “Staff”) of the Securities and Exchange Commission in its letter dated October 5, 2017 addressed to the Company relating to the above-referenced Amendment No. 1 to the Registration Statement on Form S-1 (the “Registration Statement”). Concurrently, we have filed Amendment No. 2 to the Registration Statement on Form S-1 (“Amendment No. 2”).
Set forth below in italics is comment number 1 included in the October 5, 2017 letter from the Staff and immediately following the comment is the Company’s response to that comment.
SEC Comment:
Summary Financial Information, page 12
1. Refer to your response to our prior comment 1. Your calculation of Pro forma net loss and Pro forma net loss per share includes adjustments which appear to be nonrecurring in nature. Please explain to us your consideration of Rules 11-02(b)(5) and 11-02(b)(6) of Regulation S-X.
United States Securities
and Exchange Commission
October 25, 2017
Page 2
Adial Reply:
The Company has revised its calculation of Pro forma net loss to exclude the nonrecurring charges attributable to the transaction and, accordingly, the Pro forma net loss per share as presented in the Summary Financial Information on page 12 has been revised to conform with Rule 11-02(b)(5). It has been determined by management that although the adjustments included in the Pro forma net loss (note 2 to the Summary Financial Information) in Amendment No. 1 to the Registration Statement on Form S-1 are (a) directly attributable to the transaction and (b) factually supportable; they are not expected to have a continuing impact and will be included in the net loss of the Company within 12 months following the transaction. The Pro forma net loss and Pro forma net loss per share, as well as notes 2 and 3 to the Summary Financial Information on Page 12, have been adjusted in Amendment No.2 to the Registration Statement on Form S-1 to indicate which items are not included in the Pro forma net loss and which items are included in the shares used to calculate the Pro forma net loss per common share. The Pro forma net loss continues to give effect to the conversion of the convertible debt to equity which will occur at the time of the transaction.
Please note that the Pro forma, adjusted balance sheet and footnote 4 to the Pro forma statements on page 12 have also been revised. These changes give effect to an amendment, dated October 23, 2017, to the outstanding bridge note, and are not in response to comment 1.
* * *
If you have any questions or need additional information, please contact the undersigned at (516) 496-2223 or (212) 907-6457.
Sincerely,
/s/ Leslie Marlow
Show Raw Text
CORRESP
1
filename1.htm
The Chrysler Building
405 Lexington Avenue, 26th Floor
New York, New York 10174
Telephone (212) 907-6457
Facsimile: (212) 208-4657
October 25, 2017
VIA EDGAR
United States Securities
and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 4720
Washington, D.C. 20549
Attention: Ms. Suzanne Hayes
Re:
Adial Pharmaceuticals, Inc.
Amendment No. 1 to Registration Statement on Form S-1
Filed September 25, 2017
File No: 333-220368
Dear Ms. Hayes:
On behalf of our client,
Adial Pharmaceuticals, Inc. (the “Company”), we submit this letter in response to comment 1 received from the
staff (the “Staff”) of the Securities and Exchange Commission in its letter dated October 5, 2017 addressed
to the Company relating to the above-referenced Amendment No. 1 to the Registration Statement on Form S-1 (the “Registration
Statement”). Concurrently, we have filed Amendment No. 2 to the Registration Statement on Form S-1 (“Amendment
No. 2”).
Set forth below in italics
is comment number 1 included in the October 5, 2017 letter from the Staff and immediately following the comment is the Company’s
response to that comment.
SEC Comment:
Summary Financial Information, page 12
1. Refer to your response to our prior comment 1. Your calculation of Pro forma net loss and Pro forma net loss per share includes
adjustments which appear to be nonrecurring in nature. Please explain to us your consideration of Rules 11-02(b)(5) and 11-02(b)(6)
of Regulation S-X.
United States Securities
and Exchange Commission
October 25, 2017
Page 2
Adial Reply:
The Company has revised its calculation of Pro
forma net loss to exclude the nonrecurring charges attributable to the transaction and, accordingly, the Pro forma net loss per
share as presented in the Summary Financial Information on page 12 has been revised to conform with Rule 11-02(b)(5). It has been
determined by management that although the adjustments included in the Pro forma net loss (note 2 to the Summary Financial Information)
in Amendment No. 1 to the Registration Statement on Form S-1 are (a) directly attributable to the transaction and (b) factually
supportable; they are not expected to have a continuing impact and will be included in the net loss of the Company within 12 months
following the transaction. The Pro forma net loss and Pro forma net loss per share, as well as notes 2 and 3 to the Summary Financial
Information on Page 12, have been adjusted in Amendment No.2 to the Registration Statement on Form S-1 to indicate which items
are not included in the Pro forma net loss and which items are included in the shares used to calculate the Pro forma net loss
per common share. The Pro forma net loss continues to give effect to the conversion of the convertible debt to equity which will
occur at the time of the transaction.
Please note that the Pro forma, adjusted balance
sheet and footnote 4 to the Pro forma statements on page 12 have also been revised. These changes give effect to an amendment,
dated October 23, 2017, to the outstanding bridge note, and are not in response to comment 1.
* * *
If you have any questions
or need additional information, please contact the undersigned at (516) 496-2223 or (212) 907-6457.
Sincerely,
/s/ Leslie Marlow
Leslie Marlow
cc:
William B. Stilley
Chief Executive Officer of Adial Pharmaceuticals, Inc.
Joseph Truluck
Chief Financial Officer of Adial Pharmaceuticals, Inc.